AG 555

• Description:

  AG 555 (Tyrphostin AG 555), a potent antiretroviral agent, is a potent and selective inhibitor of EGFR and blocks Cdk2 activation[1][2].

• Product Name Alternative:

  Tyrphostin AG 555

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H335

• Target:

  EGFR; Reverse Transcriptase

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/AG_555.html

• Purity:

  98.0

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  O=C(NCCCC1=CC=CC=C1)/C(C#N)=C/C2=CC=C(O)C(O)=C2

• Molecular Formula:

  C19H18N2O3

• Molecular Weight:

  322.36

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]Seri E Aflalo, et al. Tyrphostin AG-555 inhibits early and late stages of Moloney murine leukemia virus replication cycle. International Journal of Oncology. 1997.|[2]Nir Osherov, et al. Tyrphostin AG494 blocks Cdk2 activation Nir Osherov. FEBS Letters 410 (1997) 187-190.|[3]Sabine Baars, et al. Tyrphostin AG 555 Inhibits Bovine Papillomavirus Transcription by Changing the Ratio between E2 Transactivator/Repressor Function. Vol. 278, No. 39, Issue of September 26, pp. 37306–37313, 2003.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  EGFR/ErbB1/HER1

• CAS Number:

  [133550-34-2]